Cipla: Current AIDS patent pool plan is unrealistic
This article was originally published in Scrip
The Indian generic company, Cipla, claims that UNITAID's antiretrovirals (ARVs) patent pool proposal will not achieve its goals in its current form, unless country-specific patents are incorporated in the pool and details such as royalty terms and the names of all participating nations are spelt out in "unambiguous" terms.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.